Early adverse drug event signal detection within population-based health networks using sequential methods

Key methodologic considerations

Jeffrey S. Brown, Martin Kulldorff, Kenneth R. Petronis, Robert Reynolds, K. Arnold Chan, Robert Davis, David Graham, Susan E. Andrade, Marsha A. Raebel, Lisa Herrinton, Douglas Roblin, Denise Boudreau, David Smith, Jerry H. Gurwitz, Margaret J. Gunter, Richard Platt

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose Active surveillance of population-based health networks may improve the timeliness of detection of adverse events (AEs). Our objective was to expand our previous signal detection work by investigating the effect on signal detection of alternative study specifications. Methods: We compared the signal detection performance under various study specifications using historical data from nine health plans involved in the HMO Research Network's Center for Education and Research on Therapeutics (CERT). Five drug-event pairs representing generally accepted associations with an AE and two pairs representing "negative controls" were analyzed. Alternative study specifications related to the definition of incident users and incident AEs were assessed and compared to our previous findings. Results: Relaxing the incident AE exclusion criteria by (1) including members with prior outpatient diagnoses of interest and (2) halving (to 90 days) the time window specified to define incident exposure and diagnoses increased the number of members under surveillance and as a consequence increased the number of exposed days and diagnoses by about 10-20%. The alternative specifications tend to result in earlier signal detection by 10-16 months, a likely consequence of more exposures and events entering the analysis. Conclusions: This paper provides additional preliminary information related to conducting prospective safety monitoring using health plan data and sequential analytic methods. Our findings support continued investigation of using health plan data and sequential analytic methods as a potentially important contribution to active drug safety surveillance.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalPharmacoepidemiology and Drug Safety
Volume18
Issue number3
DOIs
StatePublished - Aug 27 2009

Fingerprint

Drug-Related Side Effects and Adverse Reactions
Health
Population
Population Surveillance
Therapeutic Human Experimentation
Safety
Health Maintenance Organizations
Pharmaceutical Preparations
Outpatients
Education
Research

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Pharmacology (medical)

Cite this

Early adverse drug event signal detection within population-based health networks using sequential methods : Key methodologic considerations. / Brown, Jeffrey S.; Kulldorff, Martin; Petronis, Kenneth R.; Reynolds, Robert; Chan, K. Arnold; Davis, Robert; Graham, David; Andrade, Susan E.; Raebel, Marsha A.; Herrinton, Lisa; Roblin, Douglas; Boudreau, Denise; Smith, David; Gurwitz, Jerry H.; Gunter, Margaret J.; Platt, Richard.

In: Pharmacoepidemiology and Drug Safety, Vol. 18, No. 3, 27.08.2009, p. 226-234.

Research output: Contribution to journalArticle

Brown, JS, Kulldorff, M, Petronis, KR, Reynolds, R, Chan, KA, Davis, R, Graham, D, Andrade, SE, Raebel, MA, Herrinton, L, Roblin, D, Boudreau, D, Smith, D, Gurwitz, JH, Gunter, MJ & Platt, R 2009, 'Early adverse drug event signal detection within population-based health networks using sequential methods: Key methodologic considerations', Pharmacoepidemiology and Drug Safety, vol. 18, no. 3, pp. 226-234. https://doi.org/10.1002/pds.1706
Brown, Jeffrey S. ; Kulldorff, Martin ; Petronis, Kenneth R. ; Reynolds, Robert ; Chan, K. Arnold ; Davis, Robert ; Graham, David ; Andrade, Susan E. ; Raebel, Marsha A. ; Herrinton, Lisa ; Roblin, Douglas ; Boudreau, Denise ; Smith, David ; Gurwitz, Jerry H. ; Gunter, Margaret J. ; Platt, Richard. / Early adverse drug event signal detection within population-based health networks using sequential methods : Key methodologic considerations. In: Pharmacoepidemiology and Drug Safety. 2009 ; Vol. 18, No. 3. pp. 226-234.
@article{1945c48394814cfa8b8b02f1157e243b,
title = "Early adverse drug event signal detection within population-based health networks using sequential methods: Key methodologic considerations",
abstract = "Purpose Active surveillance of population-based health networks may improve the timeliness of detection of adverse events (AEs). Our objective was to expand our previous signal detection work by investigating the effect on signal detection of alternative study specifications. Methods: We compared the signal detection performance under various study specifications using historical data from nine health plans involved in the HMO Research Network's Center for Education and Research on Therapeutics (CERT). Five drug-event pairs representing generally accepted associations with an AE and two pairs representing {"}negative controls{"} were analyzed. Alternative study specifications related to the definition of incident users and incident AEs were assessed and compared to our previous findings. Results: Relaxing the incident AE exclusion criteria by (1) including members with prior outpatient diagnoses of interest and (2) halving (to 90 days) the time window specified to define incident exposure and diagnoses increased the number of members under surveillance and as a consequence increased the number of exposed days and diagnoses by about 10-20{\%}. The alternative specifications tend to result in earlier signal detection by 10-16 months, a likely consequence of more exposures and events entering the analysis. Conclusions: This paper provides additional preliminary information related to conducting prospective safety monitoring using health plan data and sequential analytic methods. Our findings support continued investigation of using health plan data and sequential analytic methods as a potentially important contribution to active drug safety surveillance.",
author = "Brown, {Jeffrey S.} and Martin Kulldorff and Petronis, {Kenneth R.} and Robert Reynolds and Chan, {K. Arnold} and Robert Davis and David Graham and Andrade, {Susan E.} and Raebel, {Marsha A.} and Lisa Herrinton and Douglas Roblin and Denise Boudreau and David Smith and Gurwitz, {Jerry H.} and Gunter, {Margaret J.} and Richard Platt",
year = "2009",
month = "8",
day = "27",
doi = "10.1002/pds.1706",
language = "English (US)",
volume = "18",
pages = "226--234",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Early adverse drug event signal detection within population-based health networks using sequential methods

T2 - Key methodologic considerations

AU - Brown, Jeffrey S.

AU - Kulldorff, Martin

AU - Petronis, Kenneth R.

AU - Reynolds, Robert

AU - Chan, K. Arnold

AU - Davis, Robert

AU - Graham, David

AU - Andrade, Susan E.

AU - Raebel, Marsha A.

AU - Herrinton, Lisa

AU - Roblin, Douglas

AU - Boudreau, Denise

AU - Smith, David

AU - Gurwitz, Jerry H.

AU - Gunter, Margaret J.

AU - Platt, Richard

PY - 2009/8/27

Y1 - 2009/8/27

N2 - Purpose Active surveillance of population-based health networks may improve the timeliness of detection of adverse events (AEs). Our objective was to expand our previous signal detection work by investigating the effect on signal detection of alternative study specifications. Methods: We compared the signal detection performance under various study specifications using historical data from nine health plans involved in the HMO Research Network's Center for Education and Research on Therapeutics (CERT). Five drug-event pairs representing generally accepted associations with an AE and two pairs representing "negative controls" were analyzed. Alternative study specifications related to the definition of incident users and incident AEs were assessed and compared to our previous findings. Results: Relaxing the incident AE exclusion criteria by (1) including members with prior outpatient diagnoses of interest and (2) halving (to 90 days) the time window specified to define incident exposure and diagnoses increased the number of members under surveillance and as a consequence increased the number of exposed days and diagnoses by about 10-20%. The alternative specifications tend to result in earlier signal detection by 10-16 months, a likely consequence of more exposures and events entering the analysis. Conclusions: This paper provides additional preliminary information related to conducting prospective safety monitoring using health plan data and sequential analytic methods. Our findings support continued investigation of using health plan data and sequential analytic methods as a potentially important contribution to active drug safety surveillance.

AB - Purpose Active surveillance of population-based health networks may improve the timeliness of detection of adverse events (AEs). Our objective was to expand our previous signal detection work by investigating the effect on signal detection of alternative study specifications. Methods: We compared the signal detection performance under various study specifications using historical data from nine health plans involved in the HMO Research Network's Center for Education and Research on Therapeutics (CERT). Five drug-event pairs representing generally accepted associations with an AE and two pairs representing "negative controls" were analyzed. Alternative study specifications related to the definition of incident users and incident AEs were assessed and compared to our previous findings. Results: Relaxing the incident AE exclusion criteria by (1) including members with prior outpatient diagnoses of interest and (2) halving (to 90 days) the time window specified to define incident exposure and diagnoses increased the number of members under surveillance and as a consequence increased the number of exposed days and diagnoses by about 10-20%. The alternative specifications tend to result in earlier signal detection by 10-16 months, a likely consequence of more exposures and events entering the analysis. Conclusions: This paper provides additional preliminary information related to conducting prospective safety monitoring using health plan data and sequential analytic methods. Our findings support continued investigation of using health plan data and sequential analytic methods as a potentially important contribution to active drug safety surveillance.

UR - http://www.scopus.com/inward/record.url?scp=65249168893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249168893&partnerID=8YFLogxK

U2 - 10.1002/pds.1706

DO - 10.1002/pds.1706

M3 - Article

VL - 18

SP - 226

EP - 234

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -